Acta Urológica Portuguesa最新文献

筛选
英文 中文
Hérnia de Spiegel associada a criptorquidia homolateral – a propósito de um caso clínico 明镜疝伴同侧隐睾-关于一个临床病例
Acta Urológica Portuguesa Pub Date : 2015-09-01 DOI: 10.1016/j.acup.2015.08.001
Aline Vaz‐Silva, Vanda Pratas‐Vital, Fátima Alves, Dinorah Cardoso, Filipe Catela‐Mota, Paolo Casella
{"title":"Hérnia de Spiegel associada a criptorquidia homolateral – a propósito de um caso clínico","authors":"Aline Vaz‐Silva,&nbsp;Vanda Pratas‐Vital,&nbsp;Fátima Alves,&nbsp;Dinorah Cardoso,&nbsp;Filipe Catela‐Mota,&nbsp;Paolo Casella","doi":"10.1016/j.acup.2015.08.001","DOIUrl":"10.1016/j.acup.2015.08.001","url":null,"abstract":"<div><p>Spigelian hernia (SH) is an uncommon clinical entity, being particularly rare in children. While it may be associated with acquired factors, most pediatric cases appear to be due to congenital changes. SH is often associated with other congenital defects, the most frequent association being with ipsilateral cryptorchidism. The testis is often seen in the hernia sac, with no identifiable gubernaculum or inguinal canal in some cases. Given the risk of incarceration and strangulation of the contents of HS, its early diagnosis and timely treatment are essential. Treatment consists of hernia repair and extradartos orchidopexy, which should be conducted through a subcutaneous tunnel if the inguinal canal is not observed. The frequency of the association of HS and ipsilateral cryptorchidism suggests that the presence of the testis should always be confirmed at diagnosis. This association should also be taken into consideration in cases of cryptorchidism with non‐palpable testis in its normal route. In this article we present the case of an infant with a spigelian hernia associated with cryptorchidism, who underwent hernia correction and extra‐dartos orchidopexy.</p></div>","PeriodicalId":100020,"journal":{"name":"Acta Urológica Portuguesa","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.acup.2015.08.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77058278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Uso de ácido acetilsalicílico, metformina e estatinas e o cancro da próstata: impacto sobre as características patológicas e risco de recidiva bioquímica
Acta Urológica Portuguesa Pub Date : 2015-05-01 DOI: 10.1016/j.acup.2015.04.001
Virgínia Rodrigues , Emanuel Dias , Paulo Mota , Agostinho Cordeiro , Francisco Botelho
{"title":"Uso de ácido acetilsalicílico, metformina e estatinas e o cancro da próstata: impacto sobre as características patológicas e risco de recidiva bioquímica","authors":"Virgínia Rodrigues ,&nbsp;Emanuel Dias ,&nbsp;Paulo Mota ,&nbsp;Agostinho Cordeiro ,&nbsp;Francisco Botelho","doi":"10.1016/j.acup.2015.04.001","DOIUrl":"https://doi.org/10.1016/j.acup.2015.04.001","url":null,"abstract":"<div><h3>Background</h3><p>The impact of using ASA (acetylsalicylic acid), metformin and statins on the prostate cancer may be significant, but is not clear and findings from previous studies are inconsistent. This study aims to evaluate the relationship between the use of ASA, metformin and statins and the pathological characteristics and risk of biochemical recurrence (BCR) of prostate cancer.</p></div><div><h3>Methods</h3><p>A total of 311 patients submitted to radical prostatectomy (RP) at Hospital de Braga between January 2010 and June 2014 were analyzed. Data were obtained from clinical records and the crude and adjusted association between the use of a specific drug and prostate specific antigen (PSA), pathological stage, Gleason score, positive surgical margin and risk of biochemical recurrence were calculated.</p></div><div><h3>Findings</h3><p>Overall, 26 (8.4%) of the patients used ASA, 35 (11.3%) metformin and 112 (36%) statins. The ASA users had a lower PSA compared with the non users (5.9 vs. 8.9<!--> <!-->ng/m; p<!--> <!-->=<!--> <!-->0.008). Its use was an independent predictor of positive surgical margin (OR<!--> <!-->=<!--> <!-->3.77; IC 95%: 1.45‐9.78). The use of metformin was associated with advanced pathological stages, more precisely pT3b (20% vs. 7.7%; p<!--> <!-->=<!--> <!-->0.048). No other differences were detected between ASA, metformin and statins users.</p></div><div><h3>Conclusions</h3><p>The use of ASA, metformin and statins has no beneficial effect on prostatic cancer patients. On the opposite, an association between the use of metformin and advanced pathological stages was observed. These results should be validated in other larger samples and longer follow‐up. The association between the use of ASA and lower PSA was already detected in other studies, whose mechanism should be clarified in future</p></div>","PeriodicalId":100020,"journal":{"name":"Acta Urológica Portuguesa","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.acup.2015.04.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91725342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of statins and serum levels of Prostate Specific Antigen 他汀类药物的使用和前列腺特异性抗原的血清水平
Acta Urológica Portuguesa Pub Date : 2015-05-01 DOI: 10.1016/J.ACUP.2015.02.002
A. Ferro, Francisco Pina, M. Severo, P. Dias, F. Botelho, N. Lunet
{"title":"Use of statins and serum levels of Prostate Specific Antigen","authors":"A. Ferro, Francisco Pina, M. Severo, P. Dias, F. Botelho, N. Lunet","doi":"10.1016/J.ACUP.2015.02.002","DOIUrl":"https://doi.org/10.1016/J.ACUP.2015.02.002","url":null,"abstract":"","PeriodicalId":100020,"journal":{"name":"Acta Urológica Portuguesa","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88128033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Uso de ácido acetilsalicílico, metformina e estatinas e o cancro da próstata: impacto sobre as características patológicas e risco de recidiva bioquímica
Acta Urológica Portuguesa Pub Date : 2015-05-01 DOI: 10.1016/J.ACUP.2015.04.001
V. Rodrigues, E. Dias, Paulo Mota, A. Cordeiro, F. Botelho
{"title":"Uso de ácido acetilsalicílico, metformina e estatinas e o cancro da próstata: impacto sobre as características patológicas e risco de recidiva bioquímica","authors":"V. Rodrigues, E. Dias, Paulo Mota, A. Cordeiro, F. Botelho","doi":"10.1016/J.ACUP.2015.04.001","DOIUrl":"https://doi.org/10.1016/J.ACUP.2015.04.001","url":null,"abstract":"","PeriodicalId":100020,"journal":{"name":"Acta Urológica Portuguesa","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77361220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MST1R methylation as a diagnostic biomarker in renal cell tumors MST1R甲基化作为肾细胞肿瘤的诊断生物标志物
Acta Urológica Portuguesa Pub Date : 2015-05-01 DOI: 10.1016/j.acup.2015.01.004
Ana Sílvia Pires-Luís , Francisco Lobo , Márcia Vieira-Coimbra , Pedro Costa-Pinheiro , Luís Antunes , Jorge Oliveira , Rui Henrique , Carmen Jerónimo
{"title":"MST1R methylation as a diagnostic biomarker in renal cell tumors","authors":"Ana Sílvia Pires-Luís ,&nbsp;Francisco Lobo ,&nbsp;Márcia Vieira-Coimbra ,&nbsp;Pedro Costa-Pinheiro ,&nbsp;Luís Antunes ,&nbsp;Jorge Oliveira ,&nbsp;Rui Henrique ,&nbsp;Carmen Jerónimo","doi":"10.1016/j.acup.2015.01.004","DOIUrl":"https://doi.org/10.1016/j.acup.2015.01.004","url":null,"abstract":"<div><h3>Introduction</h3><p>Renal cell tumors comprise both benign – oncocytoma – and malignant – clear cell renal cell carcinoma, papillary renal cell carcinoma, and chromophobe renal cell carcinoma – entities. Since the differential diagnosis among renal cell tumors is sometimes difficult on clinical, imaging and pathological grounds, and prognosis is quite dissimilar, epigenetic-based diagnostic biomarkers, specially promoter methylation, might be useful for accurate diagnosis and therapeutic planning.</p></div><div><h3>Materials and methods</h3><p>EpiTect Methyl II PCR Array was used to screen methylation status of 22 genes, involved in epithelial to mesenchymal transition. Quantitative real-time methylation specific polymerase chain reaction was performed for candidate gene validation, and methylation levels of renal cell tumors subtypes and normal kidney were determined and compared.</p></div><div><h3>Results</h3><p>MST1R promoter methylation level was significantly higher in clear cell renal cell carcinoma (median: 5367) compared to other renal cell tumors (median: papillary renal cell carcinoma – 1084, chromophobe renal cell carcinoma – 1023, oncocytoma – 1337) and normal kidney (median: 1125), allowing for accurate discrimination from other renal cell tumors with high sensitivity (&gt;96.7%) and specificity (86.7%).</p></div><div><h3>Conclusion</h3><p>Quantitative MST1R promoter methylation may be useful as biomarker for accurate diagnosis of clear cell renal cell carcinoma in problematic cases.</p></div>","PeriodicalId":100020,"journal":{"name":"Acta Urológica Portuguesa","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.acup.2015.01.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91600103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Nefrectomia citorredutora pós‐sunitinib no carcinoma das células renais metastizado. A propósito de um caso clínico
Acta Urológica Portuguesa Pub Date : 2015-05-01 DOI: 10.1016/j.acup.2015.06.001
João Almeida Dores , Bruno Graça , Manuel Ferreira Coelho , Rita Manso , Francisco Carrasquinho Gomes
{"title":"Nefrectomia citorredutora pós‐sunitinib no carcinoma das células renais metastizado. A propósito de um caso clínico","authors":"João Almeida Dores ,&nbsp;Bruno Graça ,&nbsp;Manuel Ferreira Coelho ,&nbsp;Rita Manso ,&nbsp;Francisco Carrasquinho Gomes","doi":"10.1016/j.acup.2015.06.001","DOIUrl":"10.1016/j.acup.2015.06.001","url":null,"abstract":"<div><h3>Introduction</h3><p>Over the past three decades, nephrectomy for the treatment of patients with metastatic renal cell carcinoma (mRCC) has undergone several modifications, resulting from the implementation of systemic therapies, such as those using cytokines (IL‐2 and IFN‐α), and more recently molecular targeted therapies, such as inhibitors of angiogenesis and mTor. Using a case report as a starting point, we conducted a literature review to determine whether there is still a place for cytorreductive nephrectomy in an “era” that sees the increasing use of systemic therapies.</p></div><div><h3>Clinical case</h3><p>We present a 53‐year‐old patient who was diagnosed with metastatic RCC and underwent laparoscopic cytorreductive nephrectomy after completion of neo‐adjuvant therapy with Sunitinib.</p></div><div><h3>Discussion</h3><p>Although cytorreductive nephrectomy is associated with an increase in the overall survival of patients with metastatic RCC when it is accompanied by immunotherapy (INF‐α and IL‐2), the morbidity and mortality inherent to surgery and the positive results obtained by monotherapy regimens, including inhibitors of angiogenesis, such as Sunitinib, has launched a debate on the true benefit of nephrectomy. With this in mind, we analised studies to evaluate whether there is a benefit in administering Sunitinib before and/or after surgery, or just as part of a monotherapy regimen. We found that neo‐adjuvant Sunitinib therapy not only reduced the size of the primary renal tumor, with an increase in the overall survival of the patients, but also allowed the early detection of patients who were refractory to systemic therapy and not likely to benefit from surgery.</p></div><div><h3>Conclusion</h3><p>Preliminary studies indicate that treatment of patients with metastatic RCC will probably depend on an approach that includes both cytorreductive nephrectomy and systemic therapies</p></div>","PeriodicalId":100020,"journal":{"name":"Acta Urológica Portuguesa","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.acup.2015.06.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84078326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Divertículos da uretra feminina: uma revisão contemporânea 女性尿道憩室:当代综述
Acta Urológica Portuguesa Pub Date : 2015-05-01 DOI: 10.1016/j.acup.2015.01.001
Joana Briosa Neves , João Almeida Dores , Manuel Ferreira Coelho
{"title":"Divertículos da uretra feminina: uma revisão contemporânea","authors":"Joana Briosa Neves ,&nbsp;João Almeida Dores ,&nbsp;Manuel Ferreira Coelho","doi":"10.1016/j.acup.2015.01.001","DOIUrl":"10.1016/j.acup.2015.01.001","url":null,"abstract":"<div><h3>Introduction</h3><p>Urethral diverticula affect from 0.6 to 4.7% of women, are a frequent cause of persistent urinary symptoms and can present with complications such as lithiasis and malignization. Today, underdiagnosis and diagnostic and therapeutic delay of female urethral diverticula are still common. The aim of this article is to analyse the state of art regarding ethiology, diagnosis and therapeutics of this disease.</p></div><div><h3>Materials and methods</h3><p>Bibliographic revision of articles published until January/2014 after search of the database Medline for the keywords: “female urethral diverticula”, “female urethral diverticulum”, “urethral diverticula”, “urethral diverticulum” and “female urethra”; and of bibliographic references of the articles obtained.</p></div><div><h3>Results</h3><p>Most female urethral diverticula are secondary to infection of the periurethral and urethral glands. Despite the classically described triad of dysuria, dyspareunia and post‐void dribbling, the clinical manifestations are diverse and unspecific. Over a third are palpable on gynaecologic examination. Imaging exams, namely magnetic resonance and ultrasound, have high diagnostic capability and contribute to surgical planning. Depending on location, conformation and associated symptoms, urethral diverticula can be managed conservatively or, more frequently, surgically.</p></div><div><h3>Discussion</h3><p>Clinical evaluation is still essential for the diagnosis of female urethral diverticula. Currently, magnetic resonance is considered to be the best modality to diagnose the diverticula and to exclude pre‐ and post‐operative complications. Less invasive techniques have been described but transvaginal urethral diverticulectomy yields the highest symptomatic cure rates.</p></div><div><h3>Conclusion</h3><p>Awareness of the medical community is the most powerful weapon to reduce the underdiagnosis and diagnostic delay associated with female urethral diverticula.</p></div>","PeriodicalId":100020,"journal":{"name":"Acta Urológica Portuguesa","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.acup.2015.01.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85279257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
O papel da ressonância magnética em doentes com tumor vesical 磁共振成像在膀胱肿瘤患者中的作用
Acta Urológica Portuguesa Pub Date : 2015-05-01 DOI: 10.1016/j.acup.2015.05.001
João Magalhães Pina , Rita Nobre Lucas , João Lopes Dias , Luis Campos Pinheiro
{"title":"O papel da ressonância magnética em doentes com tumor vesical","authors":"João Magalhães Pina ,&nbsp;Rita Nobre Lucas ,&nbsp;João Lopes Dias ,&nbsp;Luis Campos Pinheiro","doi":"10.1016/j.acup.2015.05.001","DOIUrl":"10.1016/j.acup.2015.05.001","url":null,"abstract":"<div><p>Bladder cancer is one of the most common malignancies of the urinary tract. It is associated with significant morbidity and long‐term follow‐up using invasive procedures, like cystoscopy.</p><p>The initial diagnosis and staging are dependent on the histopathologic analysis of resected or biopsed samples. However, it is associated with significant under‐staging, often requiring multiple re‐staging procedures.</p><p>With the recent advances in Magnetic Resonance Imaging techniques, namely Diffusion Weighted images, it has become possible to improve the detection rate of suspicious lesions and their extension to the deep layers of the bladder wall, therefore improving staging. It is also possible to detect recurrent tumours during follow‐up and even to predict the progression rate.</p><p>With this work, the authors intend to review the current literature regarding the role of Magnetic Resonance imaging in the detection, staging and follow‐up of bladder cancer patients.</p></div>","PeriodicalId":100020,"journal":{"name":"Acta Urológica Portuguesa","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.acup.2015.05.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80827157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Use of statins and serum levels of Prostate Specific Antigen 他汀类药物的使用和前列腺特异性抗原的血清水平
Acta Urológica Portuguesa Pub Date : 2015-05-01 DOI: 10.1016/j.acup.2015.02.002
Ana Ferro , Francisco Pina , Milton Severo , Pedro Dias , Francisco Botelho , Nuno Lunet
{"title":"Use of statins and serum levels of Prostate Specific Antigen","authors":"Ana Ferro ,&nbsp;Francisco Pina ,&nbsp;Milton Severo ,&nbsp;Pedro Dias ,&nbsp;Francisco Botelho ,&nbsp;Nuno Lunet","doi":"10.1016/j.acup.2015.02.002","DOIUrl":"https://doi.org/10.1016/j.acup.2015.02.002","url":null,"abstract":"<div><h3>Objectives</h3><p>To quantify the effect of statins’ use on Prostate Specific Antigen (PSA) levels in patients referred to prostate biopsy and to determinate if the exposure to statins must be considered to improve the prostate cancer diagnostic accuracy of PSA.</p></div><div><h3>Methods</h3><p>We selected 551 subjects with PSA &lt;10.0<!--> <!-->ng/mL, referred to ultrasound guided trans-rectal prostate biopsy and classified as cancer or non-cancer patients after biopsy. Information regarding statins’ use was obtained from clinical records. We used path analysis to quantify the direct (reflects the influence on PSA biology and metabolism) indirect (reflects the influence on PSA through the effect on the risk of prostate cancer) and total effects (net result of direct and indirect effects) of statins’ use on PSA. We used Receiver Operating Characteristic curves to assess the global predictive accuracy of models including PSA, age, body mass index, 5-α-reductase inhibitors, aspirin and statins’ use for distinguishing between prostate cancer and benign conditions.</p></div><div><h3>Results</h3><p>We observed a negative total effect of statins on PSA levels (users vs. non-users: −0.633<!--> <!-->ng/mL; 95% CI: −1.087; −0.179), which corresponds to approximately 8.9% lower levels among statins’ users, mostly due to the direct effect (−0.588<!--> <!-->ng/mL; 95% CI: −1.034, −0.141) rather than that by the indirect effect (−0.045<!--> <!-->ng/mL; 95% CI: −0.152, 0.061). There were no statistically significant differences between the area under the curve corresponding to the models with or without statins (<em>P</em> <!-->=<!--> <!-->0.274).</p></div><div><h3>Conclusion</h3><p>In patients referred to prostate biopsy, statins’ use contributed to lower Prostate Specific Antigen levels, but the clinical impact in these patients is low.</p></div>","PeriodicalId":100020,"journal":{"name":"Acta Urológica Portuguesa","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.acup.2015.02.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91600102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
MST1R methylation as a diagnostic biomarker in renal cell tumors MST1R甲基化作为肾细胞肿瘤的诊断生物标志物
Acta Urológica Portuguesa Pub Date : 2015-05-01 DOI: 10.1016/J.ACUP.2015.01.004
A. S. Pires-Luís, F. Lobo, Márcia Vieira‐Coimbra, Pedro Costa-Pinheiro, L. Antunes, Jorge Oliveira, R. Henrique, C. Jerónimo
{"title":"MST1R methylation as a diagnostic biomarker in renal cell tumors","authors":"A. S. Pires-Luís, F. Lobo, Márcia Vieira‐Coimbra, Pedro Costa-Pinheiro, L. Antunes, Jorge Oliveira, R. Henrique, C. Jerónimo","doi":"10.1016/J.ACUP.2015.01.004","DOIUrl":"https://doi.org/10.1016/J.ACUP.2015.01.004","url":null,"abstract":"","PeriodicalId":100020,"journal":{"name":"Acta Urológica Portuguesa","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81982111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信